0.2290EUR0.00%Mkt Cap: 13.98M EURP/E: —Last update: 2026-06-01
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap13.98M EUR
Enterprise Value72.25M EUR
Revenue (TTM)7.66M EUR
Gross Profit3.98M EUR
Net Income (TTM)-13.66M EUR
Revenue/Share0.1440 EUR
Last Price0.2290 EUR
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees5
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012432516
Valuation
P/E (Trailing)—
P/E (Forward)0.25
PEG—
EV/EBITDA—
EV/Revenue9.44
P/S1.83
P/B-0.20
EPS (TTM)-0.26
EPS (Forward)0.92
52W Range
0.21802% of range0.7170
52W High0.7170 EUR
52W Low0.2180 EUR
Profitability
Gross Margin52.02%
Oper. Margin-89.97%
EBITDA Margin0.00%
Profit Margin-178.45%
ROE—
ROA-20.72%
Growth
Revenue Growth87.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.98M EUR
CapEx (TTM)—
FCF Margin-133.37%
FCF Yield-73.03%
Net Debt59.95M EUR
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.96
Current Ratio0.26
Quick Ratio0.23
Book Value/Sh-1.1430 EUR
Cash/Share0.0380 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.61.06M
Float—
Insiders5.73%
Institutions4.99%
Technical
SMA 500.2592 (-11.6%)
SMA 2000.2807 (-18.4%)
Beta1.31
S&P 52W Chg27.94%
Avg Vol (30d)214.44K
Avg Vol (10d)310.45K
Technical Indicators
RSI (14)36.6
MACD-0.0081
MACD Signal-0.0062
MACD Hist.-0.0019
BB Upper0.2680 EUR
BB Middle0.2470 EUR
BB Lower0.2261 EUR
BB Width16.97%
ATR (14)0.0113 EUR
Vol Ratio (20d)0.66x